FP7H2020HORIZON
Inserm Transfert SA
- Country
- FRFrance
- Defence projects
- 0
- Projects, all programmes
- 100
- As coordinator
- 2
- EU contribution (CORDIS)
- EUR 33,709,323
- Active
- 2007 to 2025
Projects
100 projects, newest first
| Project | Programme | Year | Role | EU contribution |
|---|---|---|---|---|
| EBRAEuropean Brain Research Area | H2020 | 2018 | Third party | Not stated |
| CCHFVaccineCrimean-Congo Haemorrhagic Fever Vaccine | H2020 | 2017 | Participant | EUR 401,875 |
| MEDIT-AGEINGInvestigating the impact of meditation training on mental health and wellbeing in the ageing population | H2020 | 2016 | Participant | EUR 151,675 |
| ERINHA2European Research Infrastructure on Highly Pathogenic Agents 2 | H2020 | 2016 | Participant | EUR 177,437 |
| ZIKAllianceA global alliance for Zika virus control and prevention | H2020 | 2016 | Participant | EUR 362,625 |
| EHVAEuropean HIV Vaccine Alliance (EHVA): a EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates | H2020 | 2016 | Participant | EUR 580,710 |
| JPsustaiNDCoordination Action in support of the sustainability and globalisation of the Joint Programming Initiative on Neurodegenerative Diseases | H2020 | 2015 | Participant | EUR 279,625 |
| EbolaMoDRADEbola Virus: Modern Approaches for developing bedside Rapid Diagnostics – Sofia ref.: 115843 | H2020 | 2015 | Participant | EUR 231,000 |
| MIROCALSEfficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for anti-neuroinflammatory therapy in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients | H2020 | 2015 | Participant | EUR 421,000 |
| ENSAT-HTApplication of omics-based strategies for improved diagnosis and treatment of endocrine hypertension | H2020 | 2015 | Participant | EUR 408,374 |
| FAIR-PARK-IIConservative iron chelation as a disease-modifying strategy in Parkinson’s disease: a multicentric, parallel-group, placebo-controlled, randomized clinical trial of deferiprone | H2020 | 2015 | Participant | EUR 389,491 |
| NAREBNanotherapeutics for antibiotic resistant emerging bacterial pathogens | FP7 | 2014 | Participant | EUR 479,044 |
| EXALTProposal to assess an innovative Immunotherapy, based on a thioredox peptide antigen, in a Phase I Trial for Type-1 Diabetes | FP7 | 2014 | Participant | EUR 240,018 |
| A-PARADDISEAnti-Parasitic Drug Discovery in Epigenetics | FP7 | 2014 | Participant | EUR 313,190 |
| EBOVAC2Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime-Boost Regimen: Phase II - Sofia ref.: 115861 | H2020 | 2014 | Participant | EUR 427,090 |
| BIOMARGINBiomarkers of renal graft injuries in kidney allograft recipients | FP7 | 2013 | Participant | EUR 455,400 |
| FIBRO-TARGETSTargeting cardiac fibrosis for heart failure treatment | FP7 | 2013 | Participant | EUR 400,000 |
| BRAINTRAINTaking imaging into the therapeutic domain: Self-regulation of brain systems for mental disorders | FP7 | 2013 | Participant | EUR 409,831 |
| POC-HCVPoint-of-care tests to revolutionise the clinical management of patients infected by Hepatitis C virus | FP7 | 2013 | Participant | EUR 220,120 |
| HOMAGEHeart OMics in AGEing | FP7 | 2013 | Participant | EUR 450,000 |
The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.
Where this comes from
- CORDIS: EU research projects (Horizon Europe, Horizon 2020, FP7)Last read on . Licence: Commission Decision 2011/833/EU (reuse of Commission documents). Source: CORDIS, European Commission.Participants and amounts as the Commission's CORDIS database states them (reuse under Commission Decision 2011/833/EU).
EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.
Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.
Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.